Clinical trials: Carcinoma, Non-Small-Cell Lung
Non-Small Cell Lung Cancer
A Retrospective Study of the Effectiveness and Safety of Nivolumab in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients in Japan
A Retrospective Study of the Effectiveness and Safety of Nivolumab in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients in Japan
- Trial name
- NCT03273790
- Where
- Japan
- Volunteers
- 939 people
- Sponsor
- Bristol-Myers Squibb
Non-small Cell Lung Cancer
Study of Safety, Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung Cancer
This is a Phase I study of the ALK/FAK/Pyk2 inhibitor CT-707 in patients with ALK-positive non-small cell lung cancer. The purpose of the study is to determine the MTD/RP2D of CT-707 and evaluate whether CT-707 is safe and has…
- Trial name
- NCT02695550
- Testing
- CT-707
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Centaurus Biopharma Co., Ltd.
Non-Small Cell Lung Cancer
Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies (CHANCE Trial)
This study is aimed to explore the antitumor activity and the safety profile of atezolizumab in pretreated advanced NSCLC patients with rare histological subtypes.
- Trial name
- CHANCE (NCT03976518)
- Testing
- Atezolizumab
- Where
- 10 sites in Italy
- Volunteers
- 43 people
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
Non-Small Cell Lung Cancer
A Study of Pemetrexed and Bevacizumab for Participants With Advanced Non-Small Cell Cancer
Participants with advanced non-small cell lung cancer (NSCLC) will receive a first-line treatment of Pemetrexed, Cisplatin and Bevacizumab as induction therapy followed by a maintenance treatment of Pemetrexed and Bevacizumab.
- Trial name
- NCT01004250
- Testing
- Pemetrexed, Cisplatin, Bevacizumab
- Where
- 19 sites in Denmark, Germany and 3 more
- Volunteers
- 109 people
- Sponsor
- Eli Lilly and Company
Colorectal Cancer, Breast Cancer
QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.
This is a phase 1 study to evaluate the safety, the Recommended Phase 2 Dose (RP2D), and preliminary efficacy of a personalized neoepitope yeast-based vaccine, YE-NEO-001, in subjects who have completed potentially curative…
- Conditions
- Colorectal Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma, Melanoma
- Trial name
- NCT03552718
- Testing
- YE-NEO-001
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- NantBioScience, Inc.
Advanced Non-Small Cell Lung Cancer
Pilot Study for the Determination of Tumor Response to Chemotherapy in Advanced NSCLC Through Gene Expression Profiling
Patients who are at least 18 years of age and have a type of cancer known as advanced non-small cell lung cancer may be eligible for this study if they meet all of the inclusion/exclusion criteria.
- Trial name
- NCT00161278
- Testing
- Carboplatin, Paclitaxel, Gene expression profiling (analysis) of tumor samples
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Michigan Rogel Cancer Center
Non-Small Cell Lung Cancer
Dose Escalation Study of RAD001 in Combination w/Chemotherapy & Radiation in Patients With NSCLC
The purpose of this study is to understand the effects (good and/or bad) of the addition of RAD001 to standard radiation and chemotherapy (cisplatin and pemetrexed) for patients with non-small cell lung cancer.
- Trial name
- RAD001 (NCT01063478)
- Testing
- RAD001 (in addition to standard radiation and chemotherapy)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Chicago
Non Small Cell Lung Cancer, Ovarian Cancer
Continued Access to RXDX-105
This study is being done to see if people with Non-Small Cell Lung Cancer (NSCLC) or ovarian cancer benefit from continued treatment with the study drug, RXDX-105.
- Conditions
- Non Small Cell Lung Cancer, Ovarian Cancer, RET Gene Mutation, BRAF Gene Mutation
- Trial name
- NCT03784378
- Testing
- RXDX-105
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lung Cancer (NSCLC)
Construction and Application Research of a Multidisciplinary Combined Exercise Management Program for Elderly Lung Cancer Patients After Surgery Based on Social Cognitive Theory
Informed Consent Form Protocol Title: Construction and Application Research of a Multidisciplinary Combined Exercise Management Program for Elderly Lung Cancer Patients After Surgery Based on Social Cognitive Theory Version…
- Trial name
- NCT07824778
- Testing
- Exercise Management for Elderly Lung Cancer Patients After Surgery Based on Social Cognitive Theory
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Sir Run Run Shaw Hospital
Lung Cancer, Non-Small Cell
A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor
The purpose of this study was to test a potential new kind of anti-cancer treatment, called PRAME immunotherapy in resected patients with lung cancer.
- Trial name
- PEARL (NCT01853878)
- Testing
- Recombinant PRAME protein combined with the AS15 Adjuvant System GSK2302032A
- Where
- 39 sites in United States, Estonia and 7 more
- Volunteers
- 137 people
- Sponsor
- GlaxoSmithKline
Carcinoma, Non-Small-Cell Lung
Surveillance With PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion of Definitive Therapy
The purpose of this study is to improve early detection of treatable relapse of lung cancer and thereby improve survival and quality of life for the patients.
- Trial name
- SUPE_R (NCT03740126)
- Testing
- Whole body 18F-FDG PET/CT
- Where
- 3 sites in Denmark
- Volunteers
- 750 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Immunotherapy, Chemotherapy
Adjuvant Chemotherapy Combined With Camrelizumab for ⅡA -ⅢA NSCLC Patients
Postoperative adjuvant chemotherapy followed by immunotherapy for non-small cell lung cancer has become a new treatment recommendation, but there are still many clinical problems to be solved in postoperative adjuvant…
- Trial name
- PANORAMA (NCT05825443)
- Testing
- Camrelizumab
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Advanced or Metastatic Solid Tumors
Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors
This is a first-in-human, open label, multicenter, dose escalation study of RXDX-106 in patients with locally advanced or metastatic solid tumors, who have no available therapy likely to convey clinical benefit.
- Trial name
- TITAN (NCT03454243)
- Testing
- RXDX-106
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Hoffmann-La Roche
Carcinoma, Small Cell Lung
A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer
This is a multicenter, double-blind, placebo-controlled, randomized, phase II study to investigate the efficacy and safety of Atezolizumab with or without Tiragolumab as consolidation therapy in participants with limited stage…
- Trial name
- NCT04308785
- Testing
- Atezolizumab, Tiragolumab
- Where
- 17 sites in China
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
Lung Cancer
Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC
The aim of this study is to assess the efficacy and safety of single agent AZD9291 in a real world setting in adult patients with advanced or metastatic, epidermal growth factor receptor (EGFR) T790M mutation-positive Non-Small…
- Trial name
- ASTRIS (NCT02474355)
- Testing
- T790M+ Testing, Baseline Visit Blood & Urine Testing, Baseline ECG
- Where
- 201 sites in Argentina, Australia and 14 more
- Volunteers
- 3,017 people
- Sponsor
- AstraZeneca
Lung Cancer
Sorafenib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Chemotherapy
RATIONALE: Sorafenib and erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the growth of non-small cell lung cancer by blocking blood flow to the tumor.
- Trial name
- NCT00801385
- Testing
- erlotinib hydrochloride, sorafenib tosylate, DNA analysis
- Where
- South Korea
- Volunteers
- 47 people
- Sponsor
- Yonsei University
Non-small Cell Lung Carcinoma
Evaluation of Tumor and Blood Immune Biomarkers in Resected Non-small Cell Lung Cancer
The hypothesis of this study is that functional tumor infiltrating lymphocyte (TIL) isolation from resected lung cancer specimens is feasible, allowing determination of tumor antigen-specific T cell reactivities.
- Trial name
- TOP 1502 (NCT02848872)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Duke University
Lung Cancer
Trastuzumab Plus Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00003881
- Testing
- trastuzumab, carboplatin, paclitaxel
- Where
- 71 sites in United States, Puerto Rico and 1 more
- Sponsor
- Eastern Cooperative Oncology Group
Non-small Cell Lung Cancer
Treating NSCLC Minimal Stage IV With Curative Intent
It is the hypothesis of this protocol that a subset of NSCLC patients with stage IVa disease can benefit from curative therapy and extends beyond the very limited subset of oligometastatic patients that have already been studied.
- Trial name
- NCT02054819
- Testing
- Induction chemotherapy and concurrent radiation, Consolidation: Radiation therapy to metastatic sites
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Leo W. Jenkins Cancer Center
Non-small Cell Lung Cancer
A Prospective, Open-label, Single-center, Single-arm Phase II Clinical Study of Cadonilimab (AK104) Combined With Monotherapy Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer With Negative Driver Genes and Failed Immunotherapy
The aim of evaluating the efficacy and safety of cadonilimab combined with monotherapy chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) with negative driver genes who have failed previous immunotherapy is…
- Trial name
- NCT06467500
- Testing
- Cadonilimab (AK104)
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Xin-Hua Xu
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.